Metropolis Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.

Ebitda Margin CompressionResults View source PDF Explain this filing

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.0%Reaction day

₹428.10

prior close

₹423.50

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.6%-7.6% vs market

Healthcare Service Provider peers, median of 22sector+0.1%-6.1% vs sector

On the reaction day the stock moved 7.6 pts less than Nifty Microcap 250 and 6.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-1.8

15m

-2.2

30m

-1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.0+1.6-7.6+0.1-6.1

Next day

-5.2+2.6-7.8+0.2-5.3

-3.6+3.4-7.1+0.0-3.6

-4.2+4.7-8.9-0.9-3.4

-3.1+3.6-6.6-0.4-2.6

-2.5+4.4-6.8+1.4-3.9

-4.6+4.9-9.6+0.9-5.6

15d

-1.1+6.8-7.9+0.0-1.1

-0.1+8.4-8.5+4.6-4.7

+9.6+10.0-0.4+3.6+6.0

+23.8+4.7+19.2+6.3+17.5

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Metropolis Healthcare's board approved audited Q4 and FY25 results (ended March 31, 2025) with a clean, unmodified opinion from auditor BSR & Co. LLP. Standalone revenue grew ~10.2% YoY to Rs. 1,21,654 lakhs and PAT rose ~7.7% to Rs. 12,479 lakhs, while consolidated revenue grew ~10.2% to Rs. 1,33,120 lakhs with PAT up ~13.3% to Rs. 14,551 lakhs. EBITDA/PBT margin showed mild compression compared to last year, partly due to higher depreciation and other expenses. The company completed the 100% acquisition of Core Diagnostics for Rs. 21,888 lakhs in March 2025, funded via cash and preferential share allotment. Key board decisions include re-appointment of Ameera Shah as Chairperson & Whole-time Director (5 years from March 2026), elevation of Surendran Chemmenkotil from CEO to Managing Director, and appointment of Rehan Khan as Independent Director. The board also approved a new ESOP 2025 and RSU 2025 plan, and appointed Manish Ghia & Associates and PwC as secretarial and internal auditors respectively.

Likely market impact

A clean audit and double-digit revenue growth support investor confidence, though margin compression and the sharp Q4 standalone PAT dip (~25% YoY) may temper near-term sentiment. The Core Diagnostics acquisition expands scale but brings integration risks and increased leverage; approval of new ESOP/RSU plans may cause mild dilution. Management continuity with Shah and the MD elevation should provide stability, likely positive for the stock in the medium term.